ReviewInflammopharmacology2025
Salidroside and inflammation-linked disorders: integrative insights into the pharmacological effects and mechanistic targets.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Anti-inflammatory and antioxidant effects of salidroside in diabetic nephropathy: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2026Pooled it
- Geographical Origin Drives Metabolic Divergence inMetabolites · 2026Article
- Salidroside represses ovarian cancer progression by targeting FSP1-dependent ferroptosis.Journal of ovarian research · 2026Article
- Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salidroside (SAL), a phenylpropanoid glycoside found in Rhodiola rosea L. roots, is one of the plant's most essential active components. Few studies have shown that it has many health advantages, particularly because it helps combat inflammation, prevent cell death, and protect cells from harm. Research indicated that SAL may protect cardiac myocytes from oxidative stress and enhance glucose uptake in skeletal muscle cells. It also significantly enhanced mitochondrial activity and prevented cell death in pheochromocytoma cells, SH-SY5Y neuroblastoma cells, and cardiomyocytes. Besides its advantages for cellular function, SAL is recognised for its protective effects on the heart and brain. Animal studies have shown efficacy in reducing lung damage induced by LPS and sepsis resulting from caecal ligation and puncture in murine models. SAL seems to enhance insulin resistance via activating a route that links mitochondria to AMPK, PI3K, Akt, and GSK-3β. Aqueous preparations of Rhodiola rosea have shown metabolic benefits by reducing blood glucose levels in streptozotocin-treated diabetic rats, an effect that is negated upon adrenal gland removal. The extensive array of pharmacological effects underscores the considerable therapeutic potential of SAL. Despite the well-documented advantages of SAL, research gaps persist regarding optimal dose, long-term safety, and comprehensive effectiveness comparisons in clinical environments. To assist researchers and clinicians in the biomedical sector in filling in the gaps in their knowledge and gaining a comprehensive picture of SAL's therapeutic applications and mechanisms, this review compiles the numerous results on these topics. It aims to simplify complicated material and highlight areas that need more investigation by integrating our present knowledge of SALs and their sources, biosynthesis, extraction, analysis, pharmacological effects, and molecular processes.
Indexed as
Identifiers
41003973What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.